Is Candida Auris Airborne? How the Fungus Spreads

Candida auris is not considered an airborne pathogen in the way that measles or tuberculosis are, but emerging evidence shows it can travel through the air under certain hospital conditions. The primary way C. auris spreads is through direct contact with contaminated surfaces and colonized skin, particularly in healthcare facilities. Still, a 2023 investigation in Hong Kong detected the fungus on ceiling air grilles and in air samples far from any colonized patient, raising questions about whether airborne dispersal plays a bigger role in outbreaks than previously assumed.

What the Hong Kong Air Sampling Study Found

The strongest evidence that C. auris can become airborne comes from a cardiothoracic unit outbreak in Hong Kong. Researchers found the fungus not only on frequently touched ward items, which was expected, but also on ceiling supply air grilles roughly 2.4 meters above the floor and well out of patients’ reach. Even more striking, one positive sample came from a corridor return air grille about 9.8 meters away from the area where C. auris patients were being cohorted. Passive air sampling turned up positive results too, including one from a cubicle where no confirmed case had been present for four days. Whole-genome sequencing confirmed that the air isolates, surface isolates, and patient isolates were all clonal, meaning they were genetically the same strain traveling through different routes.¹

This does not mean C. auris floats through the air the way respiratory viruses do. Airborne transmission in the infectious-disease sense usually refers to pathogens that remain suspended in tiny droplet nuclei for extended periods and travel long distances through ventilation systems. What the Hong Kong findings suggest is something more limited: skin flakes carrying C. auris cells can shed into the surrounding air, settle onto high surfaces, and get pulled into ventilation systems. The mechanism is closer to how skin-associated bacteria like MRSA sometimes turn up in hospital air than to how a cough spreads influenza.

How C. Auris Actually Spreads in Most Outbreaks

The dominant transmission pathway is contact. Patients colonized with C. auris shed the organism from their skin, and it ends up on bed rails, mattresses, bedside tables, chairs, windowsills, and medical equipment. A London cardiothoracic center outbreak involving 50 cases between 2015 and 2016 found persistent contamination across bed-space areas. The first seven U.S. cases showed that patients remained colonized on their skin and other body sites for weeks to months after their initial infection, creating ongoing opportunities to contaminate every surface they touched.²

Healthcare workers are a key link in the chain. In the same London outbreak, a healthcare worker who cared for a heavily colonized patient tested positive for C. auris on a nasal swab.² Colonized patients shed C. auris into their environment, contaminating surrounding equipment, and the organism is easily transmitted to new patients during close contact.³ This is why outbreaks cluster so tightly in long-term acute care hospitals and skilled nursing facilities, where patients share spaces and equipment for extended periods and have frequent hands-on contact with staff.

Why Surfaces Matter So Much

What sets C. auris apart from many other hospital-acquired fungi is its ability to survive on dry surfaces for weeks. Most Candida species die off fairly quickly outside the body, but C. auris persists. One reason is its capacity to form biofilms on hard surfaces. In lab testing, C. auris flourished in biofilm form on all tested surface materials.⁴ Strains that form cellular aggregates show even greater resilience, surviving for at least 14 days on surfaces, which coincides with the upregulation of genes associated with biofilm formation.⁵

The biofilm issue compounds the cleaning challenge. When C. auris forms what researchers call dry surface biofilms, it becomes more tolerant of standard disinfectants. One study found that while free-floating C. auris cells were susceptible to sodium hypochlorite (bleach), the same organism growing in dry surface biofilms showed far greater tolerance, with only modest reductions in viable cells even at the highest bleach concentrations tested.⁶ The aggregating form of C. auris remained viable 14 days after treatment with clinical concentrations of bleach in another study.⁵ This persistence explains why C. auris resists elimination even with robust decontamination procedures, and why outbreaks are so difficult to stamp out once they take hold in a facility.

Disinfection Is Harder Than It Sounds

Not all disinfectants perform equally against C. auris, and the differences matter in practice. Testing of disinfectant towelettes found that hydrogen peroxide-based and certain quaternary ammonium compound (QAC) products achieved the highest fungal reductions, while other QAC-based and QAC-alcohol products performed significantly worse.⁷ A separate study found that QAC-based disinfectants showed greater variation in effectiveness depending on which genetic clade of C. auris was being targeted, meaning a product that works well against one strain might work poorly against another.⁸

The CDC has recommended specific EPA-registered products for C. auris, and contact time is critical. A quick wipe with a disinfectant towelette is not the same as allowing the surface to remain wet for the full recommended dwell time. Healthcare facilities dealing with outbreaks typically need to adopt enhanced cleaning protocols that go well beyond standard terminal cleaning, often using UV light or hydrogen peroxide vapor as adjuncts to manual cleaning. The biofilm tolerance described above helps explain why a room that appears clean can still harbor viable C. auris and reinfect the next patient admitted to that bed.

How Outbreaks Spread Across Facilities

C. auris outbreaks tend to ripple outward from a single facility into a regional network. A telling example occurred in Orange County, California, in 2019. Initial screening at 17 facilities identified 44 patients with C. auris across all three long-term acute care hospitals and nearly half of the ventilator-capable skilled nursing facilities in the area. By October 2019, serial screenings had uncovered a total of 182 colonized patients, including the first bloodstream infection in May of that year.⁹

The pattern is consistent: patients transfer between acute care hospitals and post-acute care facilities, carrying C. auris colonization with them. Because colonization can persist for months and is often clinically silent, patients who appear healthy can introduce the organism into a new facility without anyone realizing it. Once there, the combination of prolonged surface survival, close contact, and shared equipment fuels further spread. This is why public health authorities have pushed hard for admission screening in regions where C. auris is circulating.

Screening and Early Detection

Catching colonized patients before they seed an outbreak is one of the most effective containment tools. Screening typically involves swabs from multiple body sites. A Dutch university hospital, for instance, developed a protocol that swabbed patients’ nose, throat, rectum, armpits, and groin. In the first eight months, they screened 199 patients and found seven positive cases, a rate of about 4%.¹⁰ That might sound low, but identifying even a handful of silent carriers early can prevent dozens of downstream cases.

Speed matters. Traditional culture-based methods for identifying C. auris can take several days, during which a colonized patient may already be sharing space and equipment with others. PCR-based assays have cut turnaround time substantially, allowing hospitals to isolate patients and begin enhanced environmental cleaning before the organism gets a foothold.¹¹

Genomic Tracking Reveals Hidden Transmission

Whole-genome sequencing has become an increasingly important tool for understanding how C. auris moves through healthcare networks. In a genomic analysis of C. auris transmission within an urban region, researchers identified 77 genomic clusters among 573 sequenced isolates. About a third of all sequences fell into a cluster, with most clusters being small (averaging about two to three isolates) and very closely related genetically.¹² The tight genetic clustering confirms that most transmission happens in discrete, traceable chains rather than through broad community spread.

During hospital outbreak investigations, sequencing can distinguish between cases that are genuinely linked and cases that happen to involve the same species but arrived independently. One study demonstrated how defining a range of acceptable genetic variation among isolates allowed investigators to identify two distinct transmission clusters within a single hospital outbreak, each aligning with known epidemiological connections between patients.¹³ This kind of precision helps infection control teams figure out where transmission is actually happening, rather than guessing based on which patients shared a ward.

Who Is at Risk

C. auris primarily threatens people who are already seriously ill and receiving care in healthcare facilities. The typical patient at risk has spent extended time in a hospital or long-term care setting, has a central venous catheter or other invasive medical device, has received broad-spectrum antibiotics or antifungal medications, and has a weakened immune system. Healthy people in the community are at extremely low risk. You are not going to catch C. auris from a grocery store, a gym, or a family member’s house.

This is worth emphasizing because the “superbug” framing in media coverage can make C. auris sound like a looming threat to everyone. It is a serious problem in specific healthcare environments, particularly long-term acute care hospitals and nursing facilities with ventilator-dependent patients. For the general public, the risk is negligible. The concern is really about what happens when you or someone you care about ends up in one of those high-risk settings for an extended stay.

Why Airborne Dispersal Changes the Equation, Even If It Is Not the Main Route

Even if contact transmission accounts for the vast majority of C. auris spread, the evidence of air dispersal has practical consequences for infection control. Standard contact precautions, which include gowns, gloves, and meticulous surface cleaning, are designed to interrupt the touch-based chain of transmission. They do not address organisms floating through ventilation systems or settling onto surfaces far from the colonized patient’s immediate environment.

The Hong Kong findings raise the question of whether some outbreaks that appeared puzzling, where new cases cropped up in patients who seemingly had no direct or indirect contact with known carriers, might have involved airborne dispersal as a contributing factor.¹ If skin shedding can deposit C. auris onto ceiling grilles and carry it through corridors, then ventilation design, air filtration, and negative-pressure isolation might need to enter the conversation for facilities managing active outbreaks. That said, no public health agency has yet reclassified C. auris as an airborne pathogen or recommended routine airborne precautions. The evidence is suggestive but still thin, and the overwhelming weight of outbreak data points to surfaces and hands as the drivers.

The Climate Change Hypothesis

One of the more unusual aspects of C. auris is how it appeared. The fungus was first identified in 2009 from a patient’s ear canal in Japan, but genomic analysis later revealed that distinct genetic lineages had emerged independently on multiple continents at roughly the same time. That simultaneous appearance has prompted researchers to look for a shared environmental trigger rather than a single origin point with subsequent global spread.

The leading hypothesis involves climate change. Most fungal species cannot thrive at human body temperature, which is one reason fungal infections in humans are relatively uncommon compared with bacterial or viral infections. The idea is that rising environmental temperatures may have pushed C. auris, which existed as an environmental organism, to adapt to higher temperatures over time, eventually crossing the threshold needed to survive inside a warm-blooded host.¹⁴ Supporting this idea, researchers have isolated C. auris from natural environments on the remote Andaman Islands, establishing that it does exist outside clinical settings. One of those environmental isolates grew more slowly at mammalian temperatures than clinical strains, consistent with the idea that the clinical lineages recently adapted to higher temperatures.¹⁵

The hypothesis remains unproven and comes with caveats. Other factors, including widespread agricultural use of azole antifungals and global patient travel, have almost certainly contributed to the fungus’s rise.¹⁶ But the climate angle is concerning beyond C. auris itself. If warming temperatures are eroding the thermal barrier that has historically protected mammals from environmental fungi, C. auris may be a preview of other fungal pathogens making the same leap in the coming decades.